The PUS7 Knockout SK-OV-3 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human ovarian adenocarcinoma cell line SK-OV-3, designed for loss-of-function studies of the pseudouridine synthase PUS7. This stable model features targeted disruption of the PUS7 locus via CRISPR/Cas9-mediated gene editing, enabling investigation of pseudouridylation in a cancer-relevant background. The cell line provides a powerful tool for functional genomics and cancer cell biology research.
The parental SK-OV-3 line is an epithelial cell line established from the ascites of a patient with ovarian adenocarcinoma. Widely used in ovarian cancer research, it provides a reproducible system for studying tumor cell biology, including mechanisms of proliferation, invasion, and drug resistance. Its well-characterized genetic background and adherent growth properties make it an ideal host for generating knockout models.
PUS7 encodes a pseudouridine synthase that catalyzes isomerization of uridine to pseudouridine in tRNA and mRNA substrates. It functions within larger pseudouridine synthase complexes, interacting with other complex components and RNA substrates to mediate site-specific pseudouridylation. These modifications alter RNA secondary structure, stability, and interactions with proteins, thereby modulating translation efficiency and gene expression. Downstream targets include specific tRNAs and mRNAs, with consequences for the translation machinery. Although upstream regulators are unknown, representative pathway components encompass PUS7, diverse RNA substrates, and the resulting pseudouridine nucleoside, underscoring its role in post-transcriptional regulation.
In ovarian adenocarcinoma, dysregulation of RNA modifications is increasingly implicated in tumorigenesis. By eliminating PUS7 activity in SK-OV-3 cells, this knockout model enables researchers to dissect how pseudouridylation influences ovarian cancer cell behavior. The epithelial tumor background provides a clinically relevant system for assessing impacts on RNA modification landscapes, gene expression, and oncogenic signaling, potentially revealing new biomarkers or therapeutic targets.
This cell line is suitable for a variety of experimental approaches, including pseudouridine site mapping by CMCT or mass spectrometry, RNA immunoprecipitation to validate direct RNA targets, and western blotting to assess downstream protein changes. RT-qPCR and cell proliferation assays permit quantitative functional analysis of PUS7-dependent effects on cell growth. These applications establish the PUS7 Knockout SK-OV-3 Cell Line as an essential resource for studying RNA modifications in ovarian cancer and for preclinical evaluation of pseudouridylation-targeted therapies. For additional inquiries, please contact Ascent Research.
